# EDGAR Filing Document

**Accession Number:** 0001746473
**File Stem:** 0001746473-26-000092
**Filing Date:** 2026-6
**Character Count:** 7079
**Document Hash:** 8b502bd149c999ea43578149ac70d25d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001746473-26-000092.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001746473-26-000092

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLIANT THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001746473
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474272481
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39303
- **FILM NUMBER:** 261083880

**BUSINESS ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-481-6770

**MAIL ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

?xml version='1.0' encoding='ASCII'? plrx-20260611

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

__________________________________________

**FORM 8-K**

__________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 11, 2026**

__________________________________________

**PLIANT THERAPEUTICS, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

__________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39303** | **47-4272481** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **331 Oyster Point Blvd., South San Francisco, CA** | | **94080** |
| **(Address of Principal Executive Offices)** | | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (650) 481-6770**

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)**

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | PLRX | The Nasdaq Stock Market LLC |
| Series A Junior Participating Preferred Purchase Rights | N/A | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07&nbsp;&nbsp;&nbsp;&nbsp;Submission of Matters to a Vote of Security Holders.**

The 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Pliant Therapeutics, Inc. (the "Company") was held on June 11, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 61,914,664 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2026: (i) to elect Bernard Coulie, M.D., Ph.D., MBA, Gayle Crowell, and Steve Krognes, MBA, as Class III directors of the Company to serve until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal ("Proposal No. 1"), (ii) to approve, by non-binding advisory vote, the resolution approving the compensation of the Company's named executive officers ("Proposal No. 2"), and (iii) to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 ("Proposal No. 3"). The vote results detailed below represent final results as certified by the Inspector of Elections.

**Proposal No. 1:** The Company's stockholders approved the election of each of the aforementioned Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The voting results are as follows:

---

| | | |
|:---|:---|:---|
| **<u>Nominee</u>** | **<u>For</u>** | **<u>Withhold</u>** |
| Bernard Coulie, M.D., Ph.D., MBA | 18,824,540 | 11,807,308 |
| Gayle Crowell | 18,186,914 | 12,444,934 |
| Steve Krognes, MBA | 19,299,728 | 11,332,120 |

---

The broker non-votes for Proposal No. 1 totaled 11,895,135 shares of common stock.

**Proposal No. 2:** The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers. The voting results are as follows:

---

| | | |
|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** |
| 15,282,788 | 14,572,455 | 776,605 |

---

The broker non-votes for Proposal No. 2 totaled 11,895,135 shares of common stock.

**Proposal No. 3:** The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows:

---

| | | |
|:---|:---|:---|
| **<u>For</u>** | **<u>Against</u>** | **<u>Abstain</u>** |
| 41,710,604 | 747,140 | 69,239 |

---

There were no broker non-votes for Proposal No. 3.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | PLIANT THERAPEUTICS, INC. | PLIANT THERAPEUTICS, INC. |
| Date: June 11, 2026 | By: | /s/ Keith Cummings |
|  |  | Keith Cummings, M.D., MBA |
|  |  | Chief Financial Officer |

---